Our Data

DiNardo et al. “Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered as an Oral Monotherapy in Patients with Advanced Hematologic Malignancies” ASH, December 2023

Lahr. “Discovery of IRF8 as a potential selection biomarker for FHD-609, a degrader of BRD9, in preclinical models of acute myeloid leukemia (AML)” EpiCypher, November 2023

Collins et al. “Pharmacodynamics and Mechanistic Impacts of FHD-609, a BRD9 Degrader, In a Phase 1 Study in Patients with Advanced Synovial Sarcoma or SMARCB1-Loss Tumors” CTOS, November 2023

Bellon. “Targeted Protein Degradation and The Chromatin Regulatory System” Hanson Wade’s 6th Annual Targeted Protein Degradation Summit, October 2023

Patel et al. “A Phase 1 Dose Escalation and Expansion Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, for the Treatment of Metastatic Uveal Melanoma” ESMO, October 2023

Collins et al. “Pharmacodynamics and anti-tumor mechanism of the BRG1/BRM (SMARCA4/2) inhibitor FHD-286 in a Phase 1 study in subjects with AML or MDS” AACR-NCI-EORTC, October 2023

Dominici et al. “Investigation of FHD-609, a potent degrader of BRD9, in preclinical models of acute myeloid leukemia (AML)” AACR-NCI-EORTC, October 2023

Elliott et al. “Leukemic stem cell differentiation visible at single-cell resolution in acute myeloid leukemia patients treated with FHD-286, an inhibitor of BRG1/BRM (SMARCA4/2)” AACR-NCI-EORTC, October 2023

Gartin et al. “The dual BRG1/BRM (SMARCA4/2) inhibitor FHD-286 induces functional differentiation and splicing defects in preclinical models of acute myeloid leukemia (AML)” AACR-NCI-EORTC, October 2023

Johannessen et al. “FHD-286, a potent and selective inhibitor of BRG1 and BRM, shifts metastatic uveal melanoma tumor towards a less immunosuppressive state in patient samples” AACR-NCI-EORTC, October 2023

Sandoval et al. “Treatment with dual BRG1/BRM (SMARCA4/2) inhibitor FHD-286 ablates tumor-associated androgen response elements (AREs) in prostate cancer” AACR-NCI-EORTC, October 2023

Topal et al. “Investigating the molecular role of BRD9 in synovial sarcoma” AACR-NCI-EORTC, October 2023

Wan et al. “Evaluating clinical biomarkers of FHD-286, a potent and selective inhibitor of BRG1/BRM (SMARCA4/SMARCA2), in metastatic uveal melanoma” AACR-NCI-EORTC, October 2023

Wilson et al. “Establishing the cellular and molecular impacts of the dual BRM/BRG1 (SMARCA2/SMARCA4) inhibitor FHD-286 on pre-clinical models of non-small cell lung cancer (NSCLC)” AACR-NCI-EORTC, October 2023

Zimmerman et al. “Discovery of potent and selective EP300 degraders with anti-cancer activity” AACR-NCI-EORTC, October 2023

Fiskus et al. “Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPases BRG1 and BRM by FHD-286 in cellular models of AML” AACR, April 2023

Bonte et al. “Discovery and Characterization of Potent, Selective CBP Degraders” AACR, April 2023

Collins et al. “The dual BRM/BRG1 (SMARCA2/4) inhibitor FHD-286 induces differentiation in preclinical models of acute myeloid leukemia (AML)” AACR, April 2023

Daniels. “Considerations for heterobifunctional degraders and translation to clinic” AACR, April 2023

Sappal et al. “Discovery and Characterization of Novel, Selective EP300 Degraders” AACR, April 2023

Taherbhoy. “Targeting Transcription Factor – BAF Interactions in Cancer” Drug Discovery Chemistry Meeting, April 2023

Netherton. “Discovery of FHD-609: A Potent and Selective Heterobifunctional Degrader of BRD9” Drug Discovery Chemistry Meeting, April 2023

Sherbanee et al. “Characterizing Compound Behavior at Foghorn Therapeutics” SLAS, February/March 2023

Fiskus et al. “Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPasesBRG1 and BRM by FHD-286 in cellular models of AML of diverse genetic background” ASH, December 2022

Collins et al. “Preclinical validation of target engagement assays and investigation of mechanistic impacts of FHD-609, a clinical-stage BRD9 degrader being developed for the treatment of synovial sarcoma” 2022 Connective Tissue Oncology Society Annual Meeting, November 17, 2022

Ichikawa et al. “Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models” Society for Immunotherapy of Cancer 37th Annual Meeting, November 11, 2022

Daniels. “Progressing degraders towards and through the clinic” Hanson Wade’s 5th Annual Targeted Protein Degradation Summit, October 26, 2022

Wan et al. “Biomarkers identified in preclinical studies evaluating the BRG1/BRM ATPase inhibitor FHD-286 in uveal melanoma” The 19th International Congress of the Society for Melanoma Research, October 17-20, 2022

Hentemann et al. “Pharmacological profile and anti-tumor properties of FHD-286, a novel BAF inhibitor for the treatment of transcription factor-driven cancers” AACR, April 2022

Sandoval et al. “Modulation of SPI1 transcriptional program contributes to the preclinical anti-tumor activity of SMARCA4/SMARCA2 ATPase inhibitors in AML” AACR, April 2022

Centore et al. “Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers” AACR, April 2021

Centore, Sandoval, Mendes Soares, Kadoch and Chan. “Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies” TIGS 1709 August 29, 2020

Michel et al. “A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation” Nat. Cell Biol. 2018 Dec; 20(12): 1410–1420

Kadoch & Crabtree. “Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics” Science Advances 12 Jun 2015: Vol. 1, no. 5, e1500447

Hodges, Kirkland, and Crabtree. “The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer” Advance July 13, 2016

Valencia and Kadoch. “Chromatin regulatory mechanisms and therapeutic opportunities in cancer” Nat Cell Biol. 2019 Feb; 21(2): 152–161

Sandoval et al. “Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis” 2018, Molecular Cell 71, 554–566, August 16, 2018

Learn about our platform

VIEW PLATFORM

Our insights into the biology of the chromatin regulatory system are the foundation for our proprietary platform.